You just read:

Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20

News provided by

Halozyme Therapeutics, Inc.

26 Jul, 2016, 09:00 ET